Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses

被引：0

作者：

Lei, Ming ^{[1
]}

Janjigian, Yelena Y. ^{[2
,3
]}

Ajani, Jaffer A. ^{[4
]}

Moehler, Markus ^{[5
]}

Wang, Xuya ^{[1
]}

Shen, Lin ^{[6
]}

Garrido, Marcelo ^{[7
]}

Gallardo, Carlos ^{[8
]}

Yamaguchi, Kensei ^{[9
]}

Wyrwicz, Lucjan ^{[10
]}

Skoczylas, Tomasz ^{[11
]}

Bragagnoli, Arinilda ^{[12
]}

Liu, Tianshu ^{[13
]}

Tehfe, Mustapha ^{[14
]}

Elimova, Elena ^{[15
]}

Li, Mingshun ^{[1
]}

Poulart, Valerie ^{[1
]}

Wang, Yu ^{[1
]}

Doshi, Parul ^{[1
]}

Shitara., Kohei ^{[16
]}

机构：

[1] Bristol Myers Squibb, Princeton, NJ USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Weill Cornell Med Coll, New York, NY USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Johannes Gutenberg Univ Clin, Mainz, Germany

[6] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol,Minist Educ Beijing, Beijing, Peoples R China

[7] Pontificia Univ Catolica, Clin San Carlos Apoquindo, Santiago, Chile

[8] Fdn Arturo Lopez Perez, Santiago, Chile

[9] Canc Inst Hosp JFCR, Tokyo, Japan

[10] Narodowy Inst Onkol, Klin Onkol & Radioterapii, Warsaw, Poland

[11] Med Univ Lublin, Klin Chirurg Ogolnej Gastroenterol & Nowotworow U, Lublin, Poland

[12] Fdn Pio Xii Hosp Canc Barretos, Barretos, Brazil

[13] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

[14] CHU Montreal, Oncol Ctr, Montreal, PQ, Canada

[15] Princess Margaret Canc Ctr, Toronto, ON, Canada

[16] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT023

引用

页数：3

共 50 条

[21] Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC)
Sugarman, Ryan
Nunna, Sasikiran
Betts, Keith A.
Nie, Xiaoyu
Nguyen, Hiep
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[22] First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
Liu, Tianshu
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Ruihua
Guo, Weijian
Qin, Shukui
Yang, Nong
Lu, Jianwei
Shitara, Kohei
Lei, Ming
Li, Mingshun
Bao, Nicole
Chen, Tian
Shen, Lin
INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (04) : 749 - 760
[23] A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC)
Sugarman, Ryan
Botteman, Marc
Rusibamayila, Nifasha
Nguyen, Hiep
Lin, Daniel
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[24] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Xu, R-H.
Oh, D-Y.
Kato, K.
Arkenau, H-T.
Tabernero, J.
Cruz-Correa, M.
Zimina, A. V.
Bai, Y.
Shi, J.
Lee, K-W.
Hirano, H.
Spigel, D. R.
Wyrwicz, L. S.
Pazo Cid, R. A.
Li, L.
Xu, Y.
McHenry, M. B.
Yang, S.
Moehler, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1527
[25] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Xu, R-H.
Oh, D-Y.
Kato, K.
Arkenau, T.
Tabernero, J.
Cruz-Correa, M.
Zimina, A.
Bai, Y.
Shi, J.
Lee, K-W.
Hirano, H.
Spigel, D. R.
Wyrwicz, L. S.
Cid, R. A. Pazo
Li, L.
Xu, Y.
McHenry, M. B.
Yang, S.
Moehler, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1320 - S1321
[26] Nivolumab (NIVO) plus chemotherapy (chemo) or NIVO plus ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first report of the CheckMate 648 study
Greil, R.
Chau, I
Doki, Y.
Ajani, J. A.
Xu, J.
Wyrwicz, L.
Motoyama, S.
Ogata, T.
Kawakami, H.
Hsu, C. -H
Adenis, A.
el Hajbi, F.
Di Bartolomeo, M.
Braghiroli, Ignez M.
Holtved, E.
Xynos, I
Liu, X.
Lei, M.
Kondo, K.
Kato, K.
Kitagawa, Y.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 81 - 82
[27] Q-TWiST analysis of nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC) in patients with PD-L1 CPS≥1 and CPS≥5: 4-year follow-up from CheckMate 649 (CM 649)
Lin, D.
Quan, W.
Garretson, M.
Chirikov, V. V.
Chen, C.
Singh, P.
Davis, C.
Sugarman, R.
ANNALS OF ONCOLOGY, 2024, 35 : S170 - S170
[28] Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO plus chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC/GEJC/EAC)
Chau, Ian
Barzi, Afsaneh
Zhang, Ying
You, Min
Bertwistle, David
Davis, Catherine
Chen, Clara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 295 - 295
[29] Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.
Lei, Ming
Doki, Yuichiro
Kitagawa, Yuko
Kato, Ken
Chau, Ian
Yao, Jin
Xu, Jianming
Wyrwicz, Lucjan S.
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez
Holtved, Eva
Blum Murphy, Mariela A.
Novosiadly, Ruslan
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 252 - 252
[30] Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
Chau, Ian
Doki, Yuichiro
Ajani, Jaffer A.
Xu, Jianming
Wyrwicz, Lucjan
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Freitas Melro Braghiroli, Maria Ignez
Holtved, Eva
Xynos, Ioannis
Liu, Xuan
Lei, Ming
Kondo, Kaoru
Kato, Ken
Kitagawa, Yuko
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)

← 1 2 3 4 5 →